Short answer
Adicet Bio Inc (ACET) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $972,000 (down 17.1% year over year) with net income of −$19M.
Q3 2026 key financials · XBRL
- Revenue
- $972,000
- −17.1% YoY · −16.8% QoQ
- Net income
- −$19M
- +29.7% YoY · +11.6% QoQ
- Operating margin
- -2036.6%
- EPS (diluted)
- −$1.75
- −503.4% YoY · +12.1% QoQ
Source: XBRL data from the Adicet Bio Inc (ACET) Q3 2026 10-Q on SEC EDGAR. USD.
Adicet Bio Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no products approved for commercial sale, unchanged from prior-year quarter
- Net loss $18.9M vs $26.9M YoY, operating expenses $19.8M vs $28.0M
- R&D $15.6M, down 32% YoY, worst decline from lower headcount and no new patient enrollment
- Cash, equivalents and short-term investments $100.9M at September 30, 2026, operating cash use $59.2M
- Going-concern doubt within 12 months, additional funding required, ADI-212 enrollment anticipated Q1 2027
Risk Factors
- Newly added AI regulatory risk: EU AI Act provisions effective August 2, 2026, increasing compliance obligations for high-risk systems
- Most material operational update: FDA cleared ADI-212’s IND in August 2026, with Phase 1 enrollment expected in fourth-quarter 2026
- Regulatory risk: China’s 2024 Negative List may prohibit foreign-invested entities from developing gene or stem-cell therapies
- Near-term clinical risk: prula-cel Phase 1 studies face enrollment delays from competition for eligible patients and trial sites
- Financial risk: $100.9 million in cash, equivalents and short-term Treasury investments funds operations into second-half 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adicet Bio Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.